Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.48 |
| ▸ | PRKCI | P41743 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.41 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.41 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.40 |
| ▸ | AXL | P30530 | 1/20 | 0.40 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.40 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.40 |
| ▸ | CDC7 | O00311 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.39 |
| ▸ | PIM1 | P11309 | 1/20 | 0.39 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30364924 | 1.00 | MAPT (0.48) | MAPTPRKCICYP3A4CYP2A6BRPF1 | |
| Hydrochloric Acid SCHEMBL6656724 | 0.98 | MAPT (0.47) | MAPTPRKCICYP3A4CYP2A6BRPF1 | |
| Hydrochloric Acid SCHEMBL6654905 | 0.98 | MAPT (0.47) | MAPTPRKCICYP3A4CYP2A6BRPF1 | |
| SCHEMBL720541 | 0.82 | PRKCI (0.49) | MAPTPRKCIBRPF1CDC7CDK2 | |
| SCHEMBL31735405 | 0.82 | PRKCI (0.49) | MAPTPRKCIBRPF1CDC7CDK2 | |
| SCHEMBL15712437 | 0.82 | SMN1; SMN2 (0.55) | MAPTPRKCICYP3A4BRPF1MEN1 | |
| SCHEMBL8306084 | 0.81 | CYP19A1 (0.53) | CYP3A4CYP2A6CYP2E1CYP11B2ROCK2 | |
| SCHEMBL17067754 | 0.81 | ROCK1 (0.50) | MAPTCYP3A4CYP2A6CYP2E1CYP11B2 | |
| SCHEMBL4232123 | 0.81 | ROCK1 (0.50) | CYP3A4CYP2A6CYP2E1CYP11B2CDC7 | |
| SCHEMBL6846125 | 0.80 | CYP11B2 (0.59) | MAPTCYP3A4CYP2A6CYP11B2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025245484-A1 | FOXN1 ACTIVATORS | THYMOFOX INC. (US) | 2025-11-27 | — | — | WO | disclosed |
| EP-4132907-B1 | (1H-INDOL-5-YL)ACRYLAMIDE DERIVATIVES AS INHIBITORS OF TEAD PROTEINS AND THE HIPPO-YAP1/TAZ SIGNALING CASCADE FOR THE TREATMENT OF CANCER | SANOFI SA (FR) | 2024-04-24 | — | — | EP | disclosed |
| US-20230140808-A1 | (1 H-Indol-5-YL)Acrylamide Derivatives as Inhibitors of Tead Proteins and the Hippo-YAP1/TAZ Signaling Cascade for the Treatment of Cancer | SANOFI (FR) | 2023-05-04 | — | — | US | disclosed |
| EP-4132907-A1 | (1 H-INDOL-5-YL)ACRYLAMIDE DERIVATIVES AS INHIBITORS OF TEAD PROTEINS AND THE HIPPO-YAP1/TAZ SIGNALING CASCADE FOR THE TREATMENT OF CANCER | SANOFI (FR) | 2023-02-15 | — | — | EP | disclosed |
| CN-115667216-A | (1H-indol-5-yl) acrylamide derivatives as TEAD proteins and inhibitors of the HIPPO-YAP1/TAZ signaling cascade for the treatment of cancer | 赛诺菲 | 2023-01-31 | — | — | CN | disclosed |
| EP-3892614-A1 | (1H-INDOL-5-YL)ACRYLAMIDE DERIVATIVES AS INHIBITORS OF TEAD PROTEINS AND THE HIPPO-YAP1/TAZ SIGNALING CASCADE FOR THE TREATMENT OF CANCER | SANOFI (FR) | 2021-10-13 | — | — | EP | disclosed |
| EP-2010527-B1 | 1,5 AND 3,6- SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON INC (CA) | 2013-08-14 | — | — | EP | disclosed |
| CN-101466709-B | 1,5 and 3, 6-substituted indole compounds having NOS inhibitory activity | NEURAXON INC | 2013-03-20 | — | — | CN | disclosed |
| US-7989447-B2 | 1,5 and 3,6-substituted indole compounds having NOS inhibitory activity | NEURAXON, INC. (CA) | 2011-08-02 | — | — | US | disclosed |
| US-7989447-B2 | 1,5 and 3,6-substituted indole compounds having NOS inhibitory activity | NEURAXON, INC. (CA) | 2011-08-02 | — | — | US | disclosed |
| WO-2007118314-A1 | 1,5 AND 3,6- SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON, INC. (CA) | 2007-10-25 | — | — | WO | disclosed |
| US-20040236110-A1 | Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors | BAYER PHARMACEUTICALS CORPORATION | 2004-11-25 | — | — | US | disclosed |
| EP-1432698-A2 | SUBSTITUTED 3-PYRIDYL INDOLES AND INDAZOLES AS C17,20 LYASE INHIBITORS | Bayer Pharmaceuticals Corporation (US) | 2004-06-30 | — | — | EP | disclosed |
| CN-1151147-C | Indole derivatives as 5 -HT receptor antagonist | ʷ��˿�������ȳ�ķ����˾ | 2004-05-26 | — | — | CN | disclosed |
| US-20030105139-A1 | Indole derivatives as 5-HT receptor antagonist | SMITHKLINE BEECHAM P.L.C. | 2003-06-05 | — | — | US | disclosed |
| WO-2003027094-A2 | SUBSTITUTED 3-PYRIDYL INDOLES AND INDAZOLES AS C17,20 LYASE INHIBITORS | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-04-03 | — | — | WO | disclosed |
| US-6235758-B1 | CENTRAL NERVOUS SYSTEM DISORDERS | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-05-22 | — | — | US | disclosed |
| EP-0808312-B1 | INDOLE DERIVATIVES AS 5-HT RECEPTOR ANTAGONIST | SMITHKLINE BEECHAM PLC (GB) | 2000-11-02 | — | — | EP | disclosed |
| US-5990133-A | TREATING CENTRAL NERVOUS SYSTEM DISORDERS SUCH AS ANXIETY OR DEPRESSION | SMITHKLINE BEECHAM P.L.C. (GB) | 1999-11-23 | — | — | US | disclosed |
| WO-1996023783-A1 | INDOLE DERIVATIVES AS 5-HT RECEPTOR ANTAGONIST | SMITHKLINE BEECHAM PLC (GB) | 1996-08-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040236110-A1 | Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors | CYP17A1, IDO1, CYP21A2 | MAPT 1659/4885PRKCI 3549/4885CYP3A4 98/4885 |
| US-20030105139-A1 | Indole derivatives as 5-HT receptor antagonist | HTR5A, HTR2C, HTR1A | MAPT 1035/4885PRKCI 4653/4885CYP3A4 521/4885 |
| US-20230140808-A1 | (1 H-Indol-5-YL)Acrylamide Derivatives as Inhibitors of Tead Proteins and the Hippo-YAP1/TAZ Signaling Cascade for the Treatment of Cancer | YAP1, YES1, TEAD1 | MAPT 823/4885PRKCI 893/4885CYP3A4 3458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.